Sessions Formació Continuada en Cardiologia i Especialitats Relacionades Cardioactualitat: Noves estratègies terapèutiques en el maneig de la IC
|
|
- Audra Wright
- 6 years ago
- Views:
Transcription
1 Sessions Formació Continuada en Cardiologia i Especialitats Relacionades Cardioactualitat: Noves estratègies terapèutiques en el maneig de la IC J. Comin Colet Cap de Secció del Servei de Cardiologia i Coordinador del GREC
2 Novetats Terapèutiques Recents en IC Sistòlica (ESC Congress Barcelona 2014) Regulació Autonòmica Deficiència de Ferro Antagonisme Neurohormonal
3 Novetats Terapèutiques Recents en IC Sistòlica (ESC Congress Barcelona 2014) Regulació Autonòmica Deficiència de Ferro Antagonisme Neurohormonal
4 Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet et al. for the CONFIRM-HF Investigators
5 CONFIRM-HF Study design Design: Multicentre, randomised (1:1), double-blind, placebo-controlled Main inclusion criteria: NYHA class II / III, LVEF 45% BNP > 100 pg/ml or NT-proBNP > 400 pg/ml Iron deficiency: serum ferritin <100 ng/ml or ng/ml if TSAT <20% Hb < 15 g/dl Blinding: Clinical staff: unblinded and blinded personnel Patients: usage of curtains and black syringes for injections Correction phase FCM up to 2000mg (2 x mg i.v.) Maintenance phase FCM treatment continues if ID is not corrected (500mg i.v.) Screening R FCM Placebo 1 EP: 6MWT D0 W6 W12 W24 W36 W52 Ponikowski P et al. ESC Heart Fail J 2014, in press
6 Primary endpoint: 6-minutes walking distance at week 24 LSM change in 6MWT distance from baseline (m) FCM improved 6MWT at week 24: FCM vs placebo: 33 ± 11 m (least squares mean ± standard error) P=0.002 FCM (n=150) Placebo (n=151) Week 24
7 Placebo better Odds ratio (95% CI) FCM better Placebo better Odds ratio (95% CI) FCM better Secondary endpoints: Changes in PGA & NYHA class over time Self-reported Patient Global Assessment (PGA) score No. of patients FCM Placebo P=0.29 P=0.035 P=0.047 P=0.001 P= Weeks since randomization Weeks since randomisation New York Heart Association Functional (NYHA) class P<0.001 P< P=0.004 No. of patients FCM Placebo P=0.093 P= Weeks since randomization Weeks since randomisation
8 Secondary end-point: Changes in 6MWT and Fatigue score over time Fatigue score change from baseline LSM 6MWT change from baseline LSM FCM vs placebo LSM (95% CI) P=0.16 BL ( 5, 33) P= ( 3, 35) 6MWT P= (13, 53) P< (21, 62) P< (16, 57) Weeks since randomisation FCM Placebo FCM vs placebo LSM (95% CI) Fatigue score P= P=0.40 P=0.002 P< P= Weeks since -1.4 randomisation BL ( 0.5, 0.2) 0.5 ( 0.9, 0.1) 0.6 ( 1.0, 0.2) 0.8 ( 1.2, 0.4) 0.7 ( 1.1, 0.2)
9 EQ-5D VAS change from baseline LSM Overall KCCQ score change from baseline LSM Secondary end-point: Changes in Quality of Life over time FCM vs placebo LSM (95% CI) P= ( 1.2, 4.8) P= (0.2, 6.4) KCCQ P=0.41 P=0.004 P=0.010 BL ( 1.9, 4.6) 5.0 (1.6, 8.3) 4.5 (1.1, 7.9) Weeks since randomisation FCM Placebo FCM vs placebo LSM (95% CI) P= ( 1.4, 4.4) P= ( 0.2, 5.8) EQ-5D VAS score P= ( 0.3, 5.9) P= (2.0, 8.5) P=0.120 BL ( 0.7, 5.9) Weeks since randomization
10 Secondary end-point: First hospitalization due to worsening HF Hospitalization rate (per 100 subjects) 30 Placebo FCM Log rank test P= Time (days) No. of subjects at risk Placebo FCM
11
12 Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure John J.V. McMurray, Milton Packer, Akshay S. Desai et al for the PARADIGM-HF Investigators
13 Fisiopatologia de la IC Sistòlica Damage to cardiac myocytes and extracellular matrix leads to changes in the size, shape and function of the heart and cardiac wall stress Systemic neurohormonal overactivation Vasoconstriction, fibrosis, apoptosis, hypertrophy, cellular and molecular alterations, myotoxicity Maladaptive remodeling and progressive worsening of LV function Hemodynamic alterations, salt and water retention Morbidity and mortality: arrhythmias, pump failure HF symptoms: dyspnea, edema, fatigue 13 McMurray. N Engl J Med 2010;362:228 38; Francis et al. Ann Intern Med 1984;101:370 7; Krum, Abraham. Lancet 2009;373: HFrEF* - heart failure with reduced ejection function
14 Activació Neurohormonal a la IC Natriuretic peptide system NPRs NPs Vasodilation Blood pressure Sympathetic tone Natriuresis/diuresis Vasopressin Aldosterone Fibrosis Hypertrophy HF SYMPTOMS & PROGRESSION Sympathetic nervous system Epinephrine Norepinephrine Renin angiotensin aldosterone system Ang II α 1, β 1, β 2 receptors Vasoconstriction RAAS activity Vasopressin Heart rate Contractility AT 1 R Vasoconstriction Blood pressure Sympathetic tone Aldosterone Hypertrophy Fibrosis Ang=angiotensin; AT 1 R=angiotensin II type 1 receptor; HF=heart failure; NPs=natriuretic peptides; NPRs=natriuretic peptide receptors; RAAS=renin-angiotensin-aldosterone system Levin et al. N Engl J Med 1998;339:321 8; Nathisuwan & Talbert. Pharmacotherapy 2002;22:27 42; Kemp & Conte. Cardiovascular Pathology 2012; ; Schrier & Abraham. N Engl J Med 2009;341:577 85
15 Antagonisme Neurohormonal SNS β-blockers NP system NPRs NPs Vasodilation Blood pressure Sympathetic tone Natriuresis/diuresis Vasopressin Aldosterone Fibrosis Hypertrophy INACTIVE FRAGMENTS HF SYMPTOMS & PROGRESSION Epinephrine Norepinephrine RAAS Ang II α 1, β 1, β 2 receptors Vasoconstriction RAAS activity Vasopressin Heart rate Contractility AT 1 R Vasoconstriction Blood pressure Sympathetic tone Aldosterone Hypertrophy Fibrosis RAAS inhibitors (ACEI, ARB, MRA) ACEI=angiotensin-converting-enzyme inhibitor; Ang=angiotensin; ARB=angiotensin receptor blocker; AT 1 = angiotensin II type 1; HF=heart failure; MRA=mineralocorticoid receptor antagonist; NEP=neprilysin; NP=natriuretic peptide; NPRs=natriuretic peptide receptors; RAAS=reninangiotensin-aldosterone system; SNS=sympathetic nervous system 1. McMurray et al. Eur J Heart Fail. 2013;15: ; Figure references: Levin et al. N Engl J Med 1998;339:321 8; Nathisuwan & Talbert. Pharmacotherapy 2002;22:27 42; Kemp & Conte. Cardiovascular Pathology 2012; ; Schrier & Abraham N Engl J Med 2009;341:577 85
16 Reduction in relative risk of mortality vs placebo Beneficis Aplicació Hipòtesi Neurohumoral IC Survival rates in chronic HF have improved with the introduction of new therapies 1 ACEI* β-blocker* MRA* ARB* 16% (4.5% ARR; mean follow up of 41.4 months) SOLVD-T 1,2 34% (5.5% ARR; mean follow up of 1.3 years) CIBIS-II 3 30% (11.0% ARR; mean follow up of 24 months) RALES 4 17% (3.0% ARR; median follow-up of 33.7 months) CHARM- Alternative 5 However, significant mortality remains: ~50% of patients die within 5 years of diagnosis McMurray et al. Eur Heart J 2012;33: ; 2. SOLVD Investigators. N Engl J Med 1991;325: ; 3. CIBIS-II Investigators. Lancet 1999;353:9 13; 4. Pitt et al. N Engl J Med 1999;341:709-17; 50; 5. Granger et al. Lancet 2003;362:772 6; 6. Go et al. Circulation 2014;129:e28-e292; 7. Yancy et al. Circulation 2013;128:e ; 8. Levy et al. N Engl J Med 2002;347:
17 Està tot dit en el Bloqueig Neurohormonal? SNS β-blockers NP system NPRs NPs Vasodilation Blood pressure Sympathetic tone Natriuresis/diuresis Vasopressin Aldosterone Fibrosis Hypertrophy Neprilysin inhibitors INACTIVE FRAGMENTS HF SYMPTOMS & PROGRESSION Epinephrine Norepinephrine RAAS Ang II α 1, β 1, β 2 receptors Vasoconstriction RAAS activity Vasopressin Heart rate Contractility AT 1 R Vasoconstriction Blood pressure Sympathetic tone Aldosterone Hypertrophy Fibrosis RAAS inhibitors (ACEI, ARB, MRA) ACEI=angiotensin-converting-enzyme inhibitor; Ang=angiotensin; ARB=angiotensin receptor blocker; AT 1 = angiotensin II type 1; HF=heart failure; MRA=mineralocorticoid receptor antagonist; NEP=neprilysin; NP=natriuretic peptide; NPRs=natriuretic peptide receptors; RAAS=reninangiotensin-aldosterone system; SNS=sympathetic nervous system 1. McMurray et al. Eur J Heart Fail. 2013;15: ; Figure references: Levin et al. N Engl J Med 1998;339:321 8; Nathisuwan & Talbert. Pharmacotherapy 2002;22:27 42; Kemp & Conte. Cardiovascular Pathology 2012; ; Schrier & Abraham N Engl J Med 2009;341:577 85
18 Beneficis dels Pèptids Natriurètics Endògens Release of ANP and BNP from heart and CNP in vasculature 1 Sympathetic outflow 2 Vasopressin 2 Salt appetite and water intake 2 CNP (endothelium) 3 ANP/BNP 2 Relaxation; arterial stiffness 4 Hypertrophy 2,5 7 Fibroblast proliferation 4,8,9 Na + /H 2 O loss 2 Aldosterone 2 Renin 2 Vasodilation 2,3,4 Systemic vascular resistance 4 Pulmonary artery pressure 4 Pulmonary capillary wedge pressure 4 Right atrial pressure 4 1. Forssmann et al. Arch Histol Cytol 1989;52 Suppl: ; 2. Levin et al. N Engl J Med 1998;339;321 8; 3. Lumsden et al. Curr Pharm Des 2010;16:4080 8; 4. Langenickel & Dole. Drug Discovery Today: Ther Strateg 2012;9:e131 9; 5. Gardner et al. Hypertension 2007;49:419 26; 6. Tokudome et al. Circulation 2008;117; ; 7. Horio et al. Endocrinology 2003;144: ; 8. D'Souza et al. Pharmacol Ther 2004 ;101:113 29; 9. Cao & Gardner. Hypertension 1995;25:227 34;
19 LCZ696: inhibidor del receptor de l angiotensina i de la neprilisina (ARNI en anglès) LCZ696: inhibició simultània de la NEPRILISINA + Receptor AT LCZ696 és una molècula complexe amb dues fraccions actives: 2,3 sacubitril (AHU377) un profàrmac metabolitzat a l inhibidor de la neprilisina LBQ657, + valsartan antagonista del receptor AT 1 LCZ696 en 3D 2 ARNI=angiotensin receptor neprilysin inhibitor; AT 1 =angiotensin II type 1 1. Bloch, Basile. J Clin Hypertens 2010;12:809 12; 2. Gu et al. J Clin Pharmacol 2010;50:401 14; 3. Langenickel & Dole. Drug Discov Today: Ther Strateg 2012;9:e131 9
20 LCZ696 Mecanisme Acció LCZ696 Natriuretic and other vasoactive peptides* RAAS Sacubitril (AHU377; pro-drug) Angiotensinogen (liver secretion) Ang I Inactive fragments LBQ657 (NEP inhibitor) Valsartan Ang II Enhancing Vasorelaxation Blood pressure Sympathetic tone Aldosterone levels Fibrosis Hypertrophy Natriuresis/diuresis HN O HO O OH O O N O OH N N N NH AT 1 Receptor Inhibiting Vasoconstriction Blood pressure Sympathetic tone Aldosterone Fibrosis Hypertrophy *Neprilysin substrates listed in order of relative affinity for NEP: ANP, CNP, Ang II, Ang I, adrenomedullin, substance P, bradykinin, endothelin-1, BNP Levin et al. N Engl J Med 1998;339:321 8; Nathisuwan & Talbert. Pharmacotherapy 2002;22:27 42; Schrier & Abraham N Engl J Med 2009;341:577 85; Langenickel & Dole. Drug Discov Today: Ther Strateg 2012;9:e131 9; Feng et al. Tetrahedron Letters 2012;53:275 6
21 Per què la inhibició de la NEP s ha d acompanyar de bloqueig dels AT1? Angiotensinogen Renin Ang I ACE Ang II NEP NEP Ang-(1 7) Inactive fragments AT 1 receptor Signaling cascade Biological actions Hypertrophy Fibrosis Vasoconstriction Hypertrophy Na + /H 2 O retention Aldosterone release Norepinephrine release Sympathetic tone ACE=angiotensin converting enzyme; AT 1 = angiotensin II type 1; Ang=angiotensin; NEP=neprilysin; RAAS=renin angiotensin aldosterone system 1. Von Lueder et al. Circ Heart Fail 2013;6: ; 2. Langenickel & Dole. Drug Discov Today: Ther Strateg 2012;9:e131 9
22 En que es difgerencia de l Omapatrilat Bradykinin breakdown Omapatrilat inhibits ACE, APP and NEP Active bradykinin Inactive bradykinin ACE APP NEP DPP-4 LCZ696 inhibits only NEP Active bradykinin Inactive bradykinin ACE=angiotensin-converting enzyme; APP=aminopeptidase P; AT 1 =angiotensin II type 1; DPP- 4=dipeptidyl peptidase-4; NEP=neprilysin The information presented in this slide is from publically available data and not head-to head clinical trials 1. McMurray et al. Eur J Heart Fail. 2014;16:817 25; 2. Fryer et al. Br J Pharmacol 2008;153:947 55; 3. Gu et al. J Clin Pharmacol 2010;50:401 14; 4. McMurray et al. Eur J Heart Fail. 2013;15:
23 The New Kid on The Block SNS β-blockers NP system NPRs NPs Vasodilation Blood pressure Sympathetic tone Natriuresis/diuresis Vasopressin Aldosterone Fibrosis Hypertrophy Neprilysin inhibitors INACTIVE FRAGMENTS HF SYMPTOMS & PROGRESSION LCZ696 Epinephrine Norepinephrine RAAS Ang II α 1, β 1, β 2 receptors Vasoconstriction RAAS activity Vasopressin Heart rate Contractility AT 1 R Vasoconstriction Blood pressure Sympathetic tone Aldosterone Hypertrophy Fibrosis RAAS inhibitors (ACEI, ARB, MRA) ACEI=angiotensin-converting- enzyme inhibitor; Ang=angiotensin; ARB=angiotensin receptor blocker; AT 1 = angiotensin II type 1; HF=heart failure; MRA=mineralocorticoid receptor antagonist; NEP=neprilysin; NP=natriuretic peptide; NPRs=natriuretic peptide receptors; RAAS=renin-angiotensin-aldosterone system; SNS=sympathetic nervous system 1. McMurray et al. Eur J Heart Fail. 2013;15: ; Figure references: Levin et al. N Engl J Med 1998;339:321 8; Nathisuwan & Talbert. Pharmacotherapy 2002;22:27 42; Kemp & Conte. Cardiovascular Pathology 2012; ; Schrier & Abraham N Engl J Med 2009;341:577 85
24 PARADIGM-HF: disseny de l estudi Randomization (N=8,436 patients with chronic HF [NYHA Class II IV with LVEF 40%*] and elevated NTpro-BNP or BNP) Double-blind randomized treatment period Single-blind run-in period LCZ mg BID Enalapril 10 mg BID** LCZ mg BID LCZ mg BID Enalapril 10 mg BID Testing tolerability to target doses of enalapril and LCZ696 On top of standard HF therapy (excluding ACEIs and ARBs) 2 weeks 1 2 weeks 2 4 weeks ~34 months (event-driven) *The ejection fraction entry criteria was lowered to 35% in a protocol amendment; **Enalapril 5 mg BID (10 mg TDD) for 1 2 weeks followed by enalapril 10 mg BID (20 mg TDD) as an optional starting run-in dose for those patients who are treated with ARBs or with a low dose of ACEI; 200 mg TDD; 400 mg TDD; 20 mg TDD McMurray et al. Eur J Heart Fail 2013 [Epub ahead of print] Primary outcome: CV death or HF hospitalization (event driven: 2,410 patients with primary events)
25 PARADIGM-HF: pacients Characteristic* LCZ696 Enalapril (n=4187) (n=4212) Age, years 63.8 ± ± 11.3 Women, n (%) 879 (21.0) 953 (22.6) Ischemic cardiomyopathy, n (%) 2506 (59.9) 2530 (60.1) LV ejection fraction, % 29.6 ± ± 6.3 NYHA functional class, n (%) II III 2998 (71.6) 969 (23.1) 2921 (69.3) 1049 (24.9) SBP, mmhg 122 ± ± 15 Heart rate, beats/min 72 ± ± 12 NT pro-bnp, pg/ml (IQR) 1631 ( ) 1594 ( ) BNP, pg/ml (IQR) 255 ( ) 251 ( ) History of diabetes, n (%) 1451 (34.7) 1456 (34.6) Treatments at randomization, n (%) Diuretics 3363 (80.3) 3375 (80.1) Digitalis 1223 (29.2) 1316 (31.2) β-blockers 3899 (93.1) 3912 (92.9 Mineralocorticoid antagonists 2271 (54.2) 2400 (57.0) ICD 623 (14.9) 620 (14.7) CRT 292 (7.0) 282 (6.7) *mean ± standard deviation, unless stated McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
26 Cumulative probability Primary endpoint: Death from CV causes or first hospitalization for HF Enalapril LCZ Hazard ratio = 0.80 (95% CI: ) p< Days since randomization No at risk LCZ Enalapril McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
27 Cumulative probability Components of primary endpoint: Death from CV causes Enalapril LCZ696 Hazard ratio = 0.80 (95% CI: ) p< Days since randomization No at risk LCZ Enalapril McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
28 Components of primary endpoint: First hospitalization for HF Cumulative probability 1.0 Enalapril 0.6 LCZ Hazard ratio = 0.79 (95% CI: ) p< Days since randomization No at risk LCZ Enalapril McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
29 Cumulative probability Death from any cause Enalapril LCZ696 Hazard ratio = 0.84 (95% CI: ) p< Days since randomization No at risk LCZ Enalapril McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
30 Primary outcome Outcome, n % Primary composite outcome Death from CV causes or first hospitalization for worsening of HF LCZ696 (n=4187) Enalapril (n=4212) Hazard ratio* (95% CI) p-value 914 (21.8) 1117 (26.5) 0.80 ( ) <0.001 Death from CV causes 558 (13.3) 693 (16.5) 0.80 ( ) <0.001 First hospitalization for worsening of HF 537 (12.8) 658 (15.6) 0.79 ( ) <0.001 *Calculated with the use of stratified cox proportional-hazard models Two-sided p-values calculated by means of a stratified log-rank test without adjustment for multiple comparisons The difference in favor of LCZ696 was seen early in the trial and at each interim analysis Over the duration of the trial, the numbers of patients who would need to have been treated (NNT) to prevent: one primary event was 21 patients, and one death from CV causes was 32 patients 30 McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
31 Secondary outcomes Outcome LCZ696 (n=4187) Enalapril (n=4212) Hazard ratio* or difference (95% CI) p-value Death from any cause, n (%) 711 (17.0) ) 0.84 ( ) <0.001 Change in KCCQ clinical summary score at 8 months, mean ± SD ± ± ( ) New onset atrial fibrillation, n (%) 84 (3.1) 83 (3.1) 0.97 ( ) 0.83 Decline in renal function, n (%) 94 (2.2) 108 (2.6) 0.86 ( ) 0.28 *Calculated with the use of stratified cox proportional-hazard models Two-sided p-values calculated by means of a stratified log-rank test without adjustment for multiple comparisons KCCQ scores range from 0 to 100 higher scores indicate fewer symptoms and physical limitations associated with HF 2670 patients in the LCZ696 and 2638 in the enalapril group who did not have atrial fibrillation at randomization were evaluated Defined as: (a) 50% decline in egfr from randomization; (b) > 30 ml/min/1.73 m 2 decline in egfr from randomization or to a value of <60 ml/min/1.73 m 2, or (c) progression to end-stage renal disease 31 McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
32 SAEs Event, n (%) LCZ696 (n=4187) Enalapril (n=4212) p-value Hypotension Symptomatic 588 (14.0) 388 (9.2) <0.001 Symptomatic with SBP <90 mmhg 112 (2.7) 59 (1.4) <0.001 Elevated serum creatinine 2.5 mg/dl 139 (3.3) 188 (4.5) mg/dl 63 (1.5) 83 (2.0) 0.10 Elevated serum potassium >5.5 mmol/l 674 (16.1) 727 (17.3) 0.15 >6.0 mmol/l 181 (4.3) 236 (5.6) Cough 474 (11.3) 601 (14.3) <0.001 Angioedema (adjudicated by a blinded expert committee) No treatment or use of antihistamines only 10 (0.2) 5 (0.1) 0.19 Catecholamines or glucocorticoids without hospitalization 6 (0.1) 4 (0.1) 0.52 Hospitalized without airway compromise 3 (0.1) 1 (<0.1) 0.31 Airway compromise Fewer patients in the LCZ696 group than in the enalapril group stopped their study medication because of an AE (10.7 vs 12.3%, p=0.03) 32 McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
33
34 34
35 BACKUP
36 Enalapril 10 mg BID was chosen as the appropriate comparator dose Enalapril 10 mg BID is the regulatory gold-standard ACEI based upon CONSENSUS and SOLVD-T trial data 1 3 The target dose in PARADIGM-HF was 10 mg BID, a dose comparable with that achieved in major HF trials using enalapril 3 The mean daily dose achieved in CONSENSUS and SOLVD-T was 18.4 and 16.6 mg, respectively 1,2 Key HF trials with enalapril * Trial N Target dose (mg) Mean daily dose (mg) CONSENSUS BID 18.4 SOLVD-T BID 16.6 SOLVD-P BID 16.7 V-HeFT II BID 15.0 OVERTURE BID 17.7 CARMEN BID 16.8 * Adapted from McMurray et al. Eur J Heart Fail. 2013;15: CONSENSUS Study Group. N Engl J Med 1987;316: ; 2. SOLVD Investigators. N Engl J Med 1991;325: ; 3. McMurray et al. Eur J Heart Fail. 2013;15:
37 PARADIGM-HF: LCZ696 dose selection rationale AT 1 receptor blockade LCZ mg BID delivers similar exposures to valsartan as Diovan 160 mg BID, the dose recommended for treatment of HF and MI (based on Val-HeFT and VALIANT) 1 3 Neprilysin (NEP) inhibition Biomarker analysis indicates that LCZ mg provides ~90% of its maximal NEP inhibition 4,5 Both LCZ and 200 mg QD (but not 100 mg LCZ696) provided meaningful pharmacodynamic effect (BP lowering) attributable to NEP inhibtion 5 BID dosing is considered essential to obtain 24-hour NEP inhibition 1,6 BID dosing mitigates risk of post-dose hypotension (two smaller doses, compared to one larger once-daily dose, as used in the OVERTURE study with omapatrilat) 1, McMurray et al. Eur J Heart Fail. 2013;15: ; 2. Valsartan Heart Failure Trial Investigators. N Engl J Med 2001;345: ; 3. Valsartan in Acute Myocardial Infarction Trial Investigators. N Engl J Med 2003;349: ; 4. Gu et al. J Clin Pharmacol 2010;50:401 14; 5. Ruilope et al. Lancet 2010;375: ; 6. Packer et al. Circulation 2002;106:920 6.
38 PARADIGM-HF: Key inclusion criteria Chronic HF NYHA FC II IV with LVEF 40%* BNP (or NT-proBNP) levels as follows: 150 (or 600 pg/ml), or 100 (or 400 pg/ml) and a hospitalization for HFrEF within the last 12 months 4 weeks stable treatment with an ACEI or an ARB #, and a β-blocker Aldosterone antagonist should be considered for all patients (with treatment with a stable dose for 4 weeks, if given) *The ejection fraction entry criteria was lowered to 35% in a protocol amendment # Dosage equivalent to enalapril 10 mg/day 38 McMurray et al. Eur J Heart Fail. 2013;15:
39 PARADIGM-HF: Key exclusion criteria History of angioedema egfr <30 ml/min/1.73 m 2 at screening, end of enalapril run-in or randomization, or a >35% decrease in egfr between screening and end of enalapril run-in or between screening and randomization Serum potassium >5.2 mmol/l at screening OR >5.4 mmol/l at the end of the enalapril run-in or end of the LCZ696 run-in Requirement for treatment with both ACEI and ARBs Symptomatic hypotension, SBP <100 mmhg at screening, OR SBP <95 mmhg at end of enalapril run-in or at randomization Current acute decompensated HF History of severe pulmonary disease Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid, or other major CV surgery, PCI, or carotid angioplasty within the 3 months prior to screening 39 McMurray et al. Eur J Heart Fail. 2013;15:
40 PARADIGM-HF: Primary objective To evaluate the effect of LCZ mg BID compared with enalapril 10 mg BID, in addition to conventional HFrEF treatment, in delaying time to first occurrence of either CV death or HF hospitalization 1 Rationale for endpoint selection Primary outcome of CV death or HF hospitalization was chosen as the one that best reflects the major mortality and morbidity burden of HFrEF 1,9 ~80% of deaths in recent trials in patients with HFrEF are CV related 2 4 HF is associated with a high risk of hospitalization, 5 representing the leading cause of hospitalization in patients aged 65 years 5 8 The most commonly used primary endpoint in recent HF trials: CHARM-Added, SHIFT and EMPHASIS-HF McMurray et al. Eur J Heart Fail. 2013;15: ; 2.McMurray et al. Lancet 2003;362:767 77; 3. Swedberg et al. Lancet 2010;376:875 88; 4. Zannad et al. N Engl J Med 2011;364:11 2; 5. Cowie et al. Improving care for patients with acute heart failure. Oxford Health policy Forum 2014; 6.Hunt et al. J Am Coll Cardiol 2009;53:e1 90; 7.Yancy et al. Circulation 2013;128:e ; 8.Rodriguez-Artalejo et al. Rev Esp Cardiol 2004;57:163 70; 9.Dunlay et al. Circ Cardiovasc Qual Outcomes 2011;4:68 75
41 PARADIGM-HF: Sample size and statistical considerations Annual event rate was estimated based on the CHARM-Added trial, adjusting for expected higher use of b-blockers and mineralocorticoid receptor antagonists (MRAs) Sample size was based on CV mortality 1,229 CV deaths were required for 80% power to detect a 15% relative risk reduction ~8,000 patients were required to ensure this number of events The study was event-driven: Planned to continue until 2,410 patients reached the primary composite endpoint >97% power to detect a 15% reduction in relative risk in the primary endpoint Three interim efficacy analyses were planned (after 1/3, 1/2 and 2/3 of primary events occurred) Data Monitoring Committee could recommend early trial termination based on efficacy, safety or futility reasons 41 McMurray et al. Eur J Heart Fail. 2013;15:
42 PARADIGM-HF: Secondary objectives To assess whether LCZ696 was superior to enalapril in: Improving quality of life (assessed by KCCQ score) Delaying time to all-cause mortality Delaying time to new-onset atrial fibrillation Delaying time to decline of renal function as defined by: 50% decline in egfr from baseline, or >30 ml/min/1.73 m 2 decline in egfr relative to baseline and to a value of <60 ml/min/1.73 m 2 (indicating the development of moderate renal dysfunction), or development of end-stage renal disease 42 McMurray et al. Eur J Heart Fail. 2013;15:
43 PARADIGM-HF: Exploratory objectives To compare the effects of LCZ696 and enalapril on: 43 Clinical outcomes Time to first occurrence of a composite of CV death, hospitalization for HF, non-fatal myocardial infarction, non-fatal stroke or resuscitated sudden death Hospitalization (all-cause and cause-specific) Days alive out of hospital at 12 months Time to treatment failure* Time to new onset diabetes Coronary revascularization procedure incidence Clinical composite score (NYHA class and patient global assessment) at 8 months Renal function Rate of decline in egfr Quality of life Other Quality of life assessed by total and individual scores of KCCQ and EQ-5D Biomarker changes from baseline Pharmacokinetics Health *Initiation resource of intravenous utilization treatment or a new (i.e. drug, number or an increase of in days/stays diuretic dose for >1 in month the for ICU; treatment number of worsening of HF ER visits) McMurray et al. Eur J Heart Fail. 2013;15:
44 PARADIGM-HF: Safety endpoints Monitoring for: Serious adverse events Hyperkalemia Symptomatic hypotension Increased serum creatinine Angioedema Other adverse events DMC performed a safety assessment after the first 100, 300 and 600 patients completed the single-blind run-in period Number of patients exposed to LCZ696 was limited to 600 until DMC completed a 4-week of double-blind therapy safety evaluation for the initial 200 randomized patients 44 McMurray et al. Eur J Heart Fail. 2013;15:
45 PARADIGM-HF: Patient disposition 10,513 patients entered enalapril run-in phase (median duration, 15 days; interquartile range [IQR], 14 21) 9419 entered LCZ696 run-in phase (median duration, 29 days; IQR, 26 35) 8442 underwent randomization 1102 discontinued study: 591 (5.6%) had adverse event 66 (0.6%) had abnormal laboratory or other test result 171 (1.6%) withdrew consent 138 (1.3%) had protocol deviation, administrative problem or were lost to follow-up 49 (0.5%) died 87 (0.8%) had other reasons 977 discontinued study: 547 (5.8%) had adverse event 58 (0.6%) had abnormal laboratory or other test result 100 (1.1%) withdrew consent 146 (1.6%) had protocol deviation, had administrative problem, or were lost to follow-up 47 (0.5%) died 79 (0.8%) had other reasons 43 were excluded: 6 did not undergo valid randomization 37 were from four sites prematurely closed because of major Good Clinical Practice violations 4187 were assigned to receive LCZ had known final vital status 11 had unknown final vital status 4212 were assigned to receive enalapril 4203 had known final vital status 9 had unknown final vital status McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa
46 Randomization SBP (mmhg) Systolic blood pressure during run-in and after randomization Compared with the randomization level, the mean SBP at 8 months was 3.2 ± 0.4 mmhg lower in the LCZ696 group than in the enalapril group (p<0.001) Enalapril LCZ696 Mean difference (LCZ696 enalapril): 2.70 ( 3.07, 2.34) (mmhg) p-value: < w 4m 8m 1yr 2yrs 3yrs Time When modeled as a time-dependent covariate, the difference in BP was not a determinant of the incremental benefits of LCZ McMurray, et al. N Engl J Med 2014; epub ahead of print: DOI: /NEJMoa (Supplementary appendix)
ECG in CRT patients & novel HF therapies. Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος
ECG in CRT patients & novel HF therapies Δημήτριος M. Κωνσταντίνου Ειδικός Καρδιολόγος, MD, MSc, PhD, CCDS Πανεπιστημιακός Υπότροφος Dr. Konstantinou has received grants from Medtronic Is identification
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationNeurohormonal blockade: is there still room to go?
Neurohormonal blockade: is there still room to go? M.Birhan YILMAZ, MD, FESC, FACC, FHFA Professor of Cardiology, Cumhuriyet University Sivas, TURKEY President of Heart FailureWG of Turkish Society of
More informationUNMET NEEDS IN THE MANAGEMENT OF HEART FAILURE
UNMET NEEDS IN THE MANAGEMENT OF HEART FAILURE By Mohammed Sadaka, MD ALEXANDRIA UNIVERSITY 2 Presentation Title Presenter Name Date Subject Business Use Only 1 HF is a complex syndrome involving multiple
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationSacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC
Sacubitril/Valsartan in HFrEF for All Protagonist View George Honos MD FRCPC FCCS FACC Head of Cardiology Medical Manager / CV Program CHUM Disclosure Statement Within the past two years: I have had an
More informationMEDICAL THERAPY IN HEART FAILURE
MEDICAL THERAPY IN HEART FAILURE Dr Lim Choon Pin MBBS, MRCP (UK), MMed (Int Med), FAMS, FESC, FACC Consultant Cardiologist, The Heart and Vascular Centre Heart Failure, Heart Transplant, Mechanical Circulatory
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationEffect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)
Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet Georg Ertl, Michel Komajda,
More informationHighlight Session Heart failure and cardiomyopathies Michel KOMAJDA Paris France
Highlight Session 2014 Heart failure and cardiomyopathies Michel KOMAJDA Paris France # esccongress www.escardio.org/esc2014 HEART FAILURE AND CARDIOMYOPATHIES TOPIC 1 Drug Therapy TOPIC 2 Device Therapy
More informationHFrEF and Neurohormonal Systems
HFrEF and Neurohormonal Systems Normal Control of the Circulation: Neurohumoral Balance Vasoconstrictor Salt and H 2 O retaining Vasodilator Diuretic Richard Troughton CSANZ Breakfast Symposium 15 June
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationRAAS blocker + B Blocker Troubleshooting
RAAS blocker + B Blocker Troubleshooting Heart Failure ECHO Clinic Virtual Heart Failure Consultation and Education Prof Ken McDonald & Dr. Patricia Campbell 13 th March 2017 HF activates 3 neurohormonal
More informationLCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO. Dario Leosco Università di Napoli Federico II
LCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO Dario Leosco Università di Napoli Federico II Projected changes in cardiovascular diseases CVD Deaths Increase 33% CVD DALYS 22% CAD
More informationTerapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice
Terapia Farmacologica della Insufficienza Cardiaca Cronica: è in arrivo una rivoluzione? Gennaro Cice Cattedra di Cardiologia Seconda Università di Napoli 60 CONGRESSO NAZIONALE SIGG NAPOLI, 25-28 NOVEMBRE
More informationHeFSSA Prac++oners Program 2016 What is NEW in Heart Failure treatment?
HeFSSA Prac++oners Program 2016 What is NEW in Heart Failure treatment? 08:00 Registra-on 08:25 Welcome and Thank You to Sponsors 08:30 09:15 10:00 10:30 The new kid on the block ARNI How do I effec-vely
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationPractical considerations for the use of ARNI in CHF: clinical cases. J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece
Practical considerations for the use of ARNI in CHF: clinical cases J. Parissis, Heart Failure Clinic, University of Athens, Athens, Greece Disclosures: Research grants and honoraria for lectures from
More informationChronic Heart Failure Therapies: Transforming the Landscape
Chronic Heart Failure Therapies: Transforming the Landscape Dr. Nadia Giannetti Chief of Cardiology Medical Director, Heart Failure and Heart Transplant Program McGill University Health Center Conflict
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationImproving outcomes in heart failure with reduced EF
Improving outcomes in heart failure with reduced EF Justin A. Ezekowitz, MBBCh MSc FRCPC FACC FESC FAHA Associate Professor, University of Alberta Co-Director, Canadian VIGOUR Centre Cardiologist, Mazankowski
More informationA New Future In Heart Failure (Should we reshuffle the deck?)
A New Future In Heart Failure (Should we reshuffle the deck?) DR. HEMANT SAHA, MD, MRCP(UK) AGA KHAN UNIVERSITY HOSPITAL, NAIROBI Disclosures Nothing to disclose. Objectives 1. Historical Perspectives
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationManagement of chronic heart failure: update J. Parissis Attikon University Hospital
Management of chronic heart failure: update 2015 J. Parissis Attikon University Hospital Disclosures: received honoraria for lectures from Servier, Pfizer, Novartis Discharges in Thousands Heart Failure
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationHeart Failure. Optimising treatment and balancing co-morbidity in the community. Andrew Ludman Cardiologist
Heart Failure Optimising treatment and balancing co-morbidity in the community Andrew Ludman Cardiologist What is heart failure? A structural cardiac abnormality leading to failure of the heart to provide
More informationHF TREATMENT PROGRESS
Mortality Digoxin, Diuretics, Hydralazi ne HF TREATMENT PROGRESS SOLVD CONCENSUS -16 to -31 % + ACE-I CIBIS II COPERNICUS -35 % + b- blockers RALES -22 % COMPANION & CARE HF -36 % + Aldostero ne Inhibitors
More informationOptimal Management of Heart Failure
Curriculum Vitae Name : Prof. DR. Dr. Idrus Alwi SpPD, K-KV, FACC, FESC, FAPSIC, FINASIM, FACP. Current Position : Professor of Internal Medicine Faculty of Medicine UI Medical Student : Faculty of Medicine
More informationCritical Challenges of Acute Heart Failure
Critical Challenges of Acute Heart Failure Jonathan Howlett, MD, FRCPC, FACC Libin Cardiovascular Institute and University of Calgary President, Canadian Heart Failure Society Presenter Disclosure Faculty/Presenter:
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationNew Pharmacological Developments In Heart Failure
New Pharmacological Developments In Heart Failure Diego Delgado, MD, FACC, MSc Associate Professor Site Director, Division of Cardiology Toronto General Hospital Heart Failure and Transplant Program University
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More information9/10/ , American Heart Association 2
Clyde W. Yancy, MD, MSc, MACC, FAHA, MACP Vice Dean, Diversity & Inclusion Magerstadt Professor of Medicine Professor of Medical Social Sciences Chief, Division of Cardiology Northwestern University, Feinberg
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationAndy Ignaszewski MD FRCPC Director, Heart Function Clinic PHC/UBC Vancouver, BC Canada
Andy Ignaszewski MD FRCPC Director, Heart Function Clinic PHC/UBC Vancouver, BC Canada Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationL insuffisance cardiaque chez la personne âgée
L insuffisance cardiaque chez la personne âgée Congrès d automne de la SSMIG Berne, 14.09.2017 Prof. Dr. Jean-Michel Gaspoz Département de Médecine communautaire, de premier recours et des urgences Conflicts
More informationDr Dinna Soon. Consultant Cardiologist, Department of Cardiology. GP symposium 2 April 2016
Dr Dinna Soon Consultant Cardiologist, Department of Cardiology GP symposium 2 April 2016 Case presentation 76 years old male, chronic smoker, hypertension, previous MI 3/7 SOB and chest tightness BP
More informationΝέες θεραπευτικές προσεγγίσεις για τους ασθενείς με καρδιακή ανεπάρκεια και μειωμένο κλάσμα εξωθήσεως (HFrEF).
Νέες θεραπευτικές προσεγγίσεις για τους ασθενείς με καρδιακή ανεπάρκεια και μειωμένο κλάσμα εξωθήσεως (HFrEF). ΧΑΡΑΛΑΜΠΟΣ Ι. ΚΑΡΒΟΥΝΗΣ Καθηγητής Καρδιολογίας Α.Π.Θ. Disclosures Teaching grants and honoraria
More informationIron Deficiency: New Therapeutic Target in Heart Failure. Stefan D. Anker, MD PhD
Iron Deficiency: New Therapeutic Target in Heart Failure Stefan D. Anker, MD PhD Department of Cardiology, Applied Cachexia Research, Charité Campus Virchow-Klinikum, Universitätsmedizin Berlin, Germany.
More informationHow Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationPravin Manga Division of Cardiology Department of Medicine University of Witwatersrand
Pravin Manga Division of Cardiology Department of Medicine University of Witwatersrand Overview Definition Epidemiology Biomarkers Treatment Clinical Heart Failure: Syndrome in which patients have typical
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationheart failure John McMurray University of Glasgow.
A to Z of RAAS blockade in heart failure John McMurray BHF Cardiovascular Research Centre University of Glasgow. RAAS inhibition in CHF ACE inhibition in patients with low LVEF CHF CONSENSUS Enalapril
More informationTERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018
TERAPIA DELLO SCOMPENSO DAI BETA- BLOCCANTI AGLI ARNI (ARNI SI ARNI NO) Iseo 10 Novembre 2018 Carlo Lombardi Cattedra di Cardiologia Università e Spedali Civili di Brescia All-cause mortality in the European
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationHeart Failure is the Fastest Rising Cardiovascular Condition in Canada. HF is a Progressive Condition with High Morbidity and.
Function & quality of life (QoL) Approved HF agents 1.Management of Heart Failure Patients in Ontario: Recommendations from Best Practice, April 213, *Ross et al. Treating the right patient at the right
More informationDoes My Patient Always Require Diuretics???
Does My Patient Always Require Diuretics??? Shelley Zieroth, MD Associate Professor, Section of Cardiology Director, SBH Heart Failure and Transplant Clinics Head, Medical Heart Failure Program WRHA Cardiac
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationUse of Sacubitril/Valsartan in Heart Failure
Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal
More informationA new class of drugs for systolic heart failure: The PARADIGM-HF study
INTERPRETING KEY TRIALS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will describe the mechanism and use of angiotensin receptor-neprilysin inhibitors in heart failure MARWA A. SABE, MD, MPH Department of
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationHeart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis. More malignant than cancer
Patients in US (millions) Heart Failure (HF): Scope of the Problem 1 8 6 4 2 3.5 4.8 1. 1991 21 237 US prevalence*: 5.8 million US annual incidence: 67, Annual mortality: 282,754 5-1% depending on severity
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationINIBITORI NEPRILISINA
INIBITORI NEPRILISINA Marco Canepa, MD, PhD Università degli Studi di Genova Cardiologia, Ospedale Policlinico San Martino IRCCS marco.canepa@unige.it ARNI: ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITORS
More informationSacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data,
Sacubitril/Valsartan unter der Lupe Subgruppenanalysen, real world data, praktische Erfahrungen michael.boehm@uks.eu M. Böhm Innere Medizin III (Kardiologie / Angiologie / Internistische Intensivmedizin)
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationLearning Objectives. Heart Failure (HF): Scope of the Problem. Temporal Trends in Age-Adjusted Survival After HF Diagnosis
7:5 :5 am Update in Heart Failure SPEAKER Orly Vardeny, PharmD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Orly Vardeny, PharmD, MS: Advisory Board
More informationESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Patients t with acute heart failure frequently develop chronic heart failure Patients with chronic heart failure frequently decompensate acutely ESC Guidelines for the Diagnosis and A clinical response
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationAngiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure
Original Article Angiotensin Neprilysin Inhibition in Acute Decompensated Heart Failure Eric J. Velazquez, M.D., David A. Morrow, M.D., M.P.H., Adam D. DeVore, M.D., M.H.S., Carol I. Duffy, D.O., Andrew
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationCT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD
CT Academy of Family Physicians Scientific Symposium October 2012 Amit Pursnani, MD Clinical syndrome resulting from a structural or functional cardiac disorder that impairs the ability of the heart to
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationChronic Heart Failure. Dr Eric Klug Heart Failure Clinic: CM Johannesburg Academic Hospital. Sunninghill and Sunward Park Hospitals
Chronic Heart Failure Dr Eric Klug Heart Failure Clinic: CM Johannesburg Academic Hospital. Sunninghill and Sunward Park Hospitals The most important slide: The challenge of chronic The good physician
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationBehandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion
Behandlungsalgorithmus bei Herzinsuffizienz mit reduzierter Auswurffraktion Professor Dr. med. Roger Hullin Leiter Programm für Schwere Herzinsuffizienz, VAD & Herztransplantation Suisse Romande Klinik
More informationSynopsis. Study title. Investigational Product Indication Design of clinical trial. Number of trial sites Duration of clinical trial / Timetable
Synopsis Study title Investigational Product Indication Design of clinical trial Number of trial sites Duration of clinical trial / Timetable Repetitive levosimendan infusions for patients with advanced
More informationThe Myths of Heart Failure with Preserved Ejection Fraction:
The Myths of Heart Failure with Preserved Ejection Fraction: A misunderstood disease in search of a therapy Scott D. Solomon, MD The Edward D. Frohlich Distinguished Chair Professor of Medicine Harvard
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST TAKE HOME MESSAGES FROM RECENT HEART FAILURE CLINICAL TRIALS How to use aldosterone blockers? Faiez Zannad INSERM, U961 and Clinical Investigation Center CHU, Heart
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More information